Abstract
It is unfortunate that the results in the Waxman et al. article are unclear. 1 We have reanalyzed the data without this article and found that the relative risks (RR) changes only modestly and in the direction of our original conclusion. 2 Without the Waxman article, the RR for ovarian preservation is 1.75 (1.41-2.17) and for pregnancy following therapy is 1.69 (1.05-2.72). Both analyses indicate that women who received GnRH agonist (GnRHa) cotherapy had a higher likelihood of preserving ovarian function and becoming pregnant than did women who did not receive the GnRHa. We appreciate Dr. Blumenfeld's attention to the more recent reports of further success with GnRHa cotherapy leading to improved ovarian preservation. 3